A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Naomi Hunder, MD
Silverback Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Macquarie University Hospital Clinical Trials Unit
Sydney, New South Wales, Australia
- Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
- Breast Cancer Research Centre - Wa
Nedlands, Western Australia, Australia
- Asan Medical Center
Seoul, South Korea
- Samsung Medical Center
Seoul, South Korea
- Seoul National University Hospital
Seoul, South Korea
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Duke University
Durham, North Carolina, United States
- University of Pittsburgh Medical Center Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
- Sarah Cannon Research Institute/tennessee Oncology
Nashville, Tennessee, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- the Start Center for Cancer Care
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Jul 2020
- Primary completion
- 31 Dec 2022
- Completion
- 31 Dec 2022
- Last update posted
- 30 Jun 2022
- Registered enrollment
- 58
- Registry id
- NCT04460456
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.